Objectives: The goal of the study was to determine short- and long-term success and complications of radiofrequency atrioventricular (AV) junction catheter ablation and to compare these with those of high energy direct current catheter ablation.

Background: Catheter ablation of the AV junction with radiofrequency or direct current energy is an accepted treatment for drug-refractory supraventricular tachycardias. Few data are available on the long-term success and effects of radiofrequency ablation or its comparison with direct current ablation.

Methods: Fifty-four patients who underwent attempted AV junction ablation with radiofrequency energy were followed up for a mean of 24 +/- 8.4 months. These patients were retrospectively compared with 49 patients who underwent attempted AV junction ablation with direct current energy and were followed up for a mean of 41 +/- 23 months.

Results: The early success rate at the time of discharge for radiofrequency ablation was 81.5%, which was not statistically different from that for direct current ablation (85.7%). Fewer sessions were required to achieve complete AV block in the radiofrequency group (1.05 +/- 0.23) (mean +/- SD) compared with the direct current group (1.21 +/- 0.41) (p = 0.02). Although overall complication rates were similar for both groups (9.3% in the radiofrequency group and 8.2% in the direct current group), there was a trend toward more life-threatening early complications in those patients who received direct-current shocks (6.8%) than in those who underwent radiofrequency ablation alone (2.3%) (p = 0.1). Early sudden death (one patient), early ventricular tachycardia (two patients) and cardiac tamponade (one patient) were seen only in those patients who underwent ablation with direct current energy, whereas pulmonary embolism (one patient) was the only early life-threatening complication in the radiofrequency group. During follow-up, the rate of recurrence of AV conduction was the same (5%) for both the direct current and radiofrequency groups. In the direct current group, one patient died suddenly 2 weeks after the procedure and another had a cardiac arrest due to ventricular tachycardia 6 h after the procedure. In the radiofrequency group, two patients died suddenly at 11 and 7 months, respectively. Two patients, one who had unsuccessful radiofrequency ablation and required direct current ablation, were resuscitated from ventricular tachycardia.

Conclusions: Radiofrequency energy appears to be as efficacious as and perhaps safer than direct current energy for AV junction ablation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0735-1097(93)90084-eDOI Listing

Publication Analysis

Top Keywords

direct current
52
current energy
16
radiofrequency ablation
16
radiofrequency group
16
radiofrequency
14
direct
13
current
13
ablation
13
catheter ablation
12
patients underwent
12

Similar Publications

Polymer material innovations for a green hydrogen economy.

Chem Commun (Camb)

January 2025

Institute of Sustainability for Chemicals, Energy and Environment (ISCE2), Agency for Science, Technology and Research (A*STAR), 1 Pesek Road, Singapore 627833, Republic of Singapore.

Polymeric materials are ubiquitous in modern life. Similar to many other technological applications, polymer materials are essential in advancing the green hydrogen economy, offering solutions for hydrogen production, storage, transport, and utilization. In production, polymeric proton exchange membranes in water electrolysers enable efficient green hydrogen generation using renewable energy.

View Article and Find Full Text PDF

Pricing for Multi-Indication Drugs in the Italian Regulatory Context.

Pharmacoecon Open

January 2025

HTA & Pharmaceutical Economics Department, Italian Medicines Agency (AIFA), Rome, Italy.

Background: The authorization of new therapeutic indications for drugs already reimbursed by the Italian National Health Service (NHS) represents a matter of importance. This study aims to estimate the additional discount attributed to the extension of indications (EoIs) to explore the potential correlation between spending and negotiated discounts and to find specific factors (determinants) that impact on discount.

Methods: The study focused on drugs approved in Italy between 2003 and 2017 with at least four therapeutic indications, including the first approved and EoIs, with follow-up extended until 2021 to acquire all the information on the negotiation process that has been completed.

View Article and Find Full Text PDF

Purpose: MMQ1 is a Danish-language patient-reported outcome measure (PROM) for quality of life (QOL) in people with multiple long-term conditions (MLTC). It measures needs-based QOL across six scales: Physical ability, Concerns and worries, Limitations in daily life, Social life, Personal finances and Self-image. There is currently no such measure available in English.

View Article and Find Full Text PDF

Early brain injury (EBI) after subarachnoid hemorrhage (SAH) is a clear correlation with poor prognosis. In the past 20 years, the research on EBI has increased rapidly. However, there is a lack of bibliometric analysis related to EBI.

View Article and Find Full Text PDF

Cushing's syndrome related to higher rates and earlier onset of cataract: A nationwide retrospective cohort study.

Graefes Arch Clin Exp Ophthalmol

January 2025

School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Purpose: To investigate the risk of cataract in patients with Cushing's syndrome (CS) and evaluate whether disease onset occurs at an earlier age compared to general population.

Methods: A nationwide retrospective matched-cohort study including individuals diagnosed with endogenous CS from 2000 to 2023. Patients with CS were matched in a 1:5 ratio with a control group individually matched for age, sex, socioeconomic status, and body mass index.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!